Genenta Science (GNTA) Stock Price, News & Analysis

Company Overview

Genenta Science (NASDAQ: GNTA) is a clinical-stage biotechnology company focused on the development of in vivo hematopoietic stem cell (HSC) gene therapies for the treatment of solid tumors. The company’s proprietary platform enables the transplantation of genetically engineered HSCs that home to tumor sites and continuously deliver immunomodulatory agents. By harnessing the patient’s own stem cells, Genenta aims to establish a sustained, localized anti-tumor immune response with the potential to overcome limitations of traditional cytokine or antibody therapies.

Genenta’s lead product candidate, Temferon, consists of autologous HSCs engineered to produce interferon-alpha under the control of a tumor microenvironment–activated promoter. Temferon is currently being evaluated in Phase I/II clinical trials for recurrent high-grade glioma and ovarian carcinoma. Early clinical data have demonstrated a favorable safety profile and promising signs of biological activity, supporting the company’s approach to create a durable anticancer effect while limiting systemic toxicity.

Headquartered in Milan, Italy, with a research and development presence in the United States, Genenta Science collaborates with academic institutions and cancer centers across Europe and North America to advance its clinical programs. The company benefits from strategic partnerships that provide access to leading oncology experts, manufacturing capabilities, and patient networks, positioning it to accelerate enrollment in multi-center trials and to expand its pipeline.

Founded in 2016 as a spin-off from leading academic research institutes, Genenta Science is led by a management team with extensive experience in gene therapy, hematology, and oncology drug development. The company has attracted funding from both private investors and non-dilutive sources to support its growth, with the goal of bringing novel HSC-based immunotherapies to patients with hard-to-treat solid tumors.

Key Stats

• Today's Range: $0.59 to $0.65
• 50-Day Range: $0.59 to $0.88
• 52-Week Range: $0.55 to $10.00
• Volume: 37,424 shs
• Average Volume: 692,980 shs
• Market Capitalization: $13.92 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: Sell

Genenta Science Stock Analysis - MarketRank™

Genenta Science scored higher than 18% of companies evaluated by MarketBeat, and ranked 800th out of 858 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 0.7 / 5
• Analyst Rating: Sell

Consensus Rating

Genenta Science has received a consensus rating of Sell. The company's average rating score is 1.00, and is based on no strong buy ratings, no buy ratings, no hold ratings, and 1 sell rating.

Amount of Analyst Coverage

Genenta Science has only been the subject of 1 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: N/A

Price to Book Value per Share Ratio

Genenta Science has a P/B Ratio of 0.46. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: 5.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

0.08% of the float of Genenta Science has been sold short.

Short Interest Ratio / Days to Cover

Genenta Science has a short interest ratio ("days to cover") of 0.31, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Genenta Science has recently decreased by 78.73%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Genenta Science does not currently pay a dividend.

Dividend Growth

Genenta Science does not have a long track record of dividend growth.

News and Social Media

• Score: N/A
• News Sentiment: N/A

Company Ownership

• Score: 0.9 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Genenta Science insiders have not sold or bought any company stock.

Percentage Held by Insiders

28.99% of the stock of Genenta Science is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

15.13% of the stock of Genenta Science is held by institutions.

Company Calendar

• Last Earnings: 3/31/2026
• Today: 5/21/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:GNTA
• CIK: 1838716
• Web: www.genenta.com
• Phone: 39-02-2643-4681
• Fax: N/A
• Employees: 7
• Year Founded: 2014

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: 0.35
• Current Ratio: 14.16
• Quick Ratio: 14.16

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $1.29 per share
• Price / Book: 0.46

Miscellaneous

• Outstanding Shares: 23,590,000
• Free Float: 16,752,000
• Market Cap: $13.92 million
• Optionable: Not Optionable
• Beta: 0.74